SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:252b1123-0add-435c-b8df-75987f97e0ac"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:252b1123-0add-435c-b8df-75987f97e0ac" > Anaplastic thyroid ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005303naa a2200745 4500
001oai:lup.lub.lu.se:252b1123-0add-435c-b8df-75987f97e0ac
003SwePub
008160401s2002 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1951485
0247 a https://lup.lub.lu.se/record/1090242 URI
0247 a https://doi.org/10.1038/sj.bjc.66003612 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19514852 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Tennvall, Janu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-jte
2451 0a Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.
264 c 2002-06-11
264 1b Springer Science and Business Media LLC,c 2002
520 a Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery. Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gyx2 (A) and 1989-92 1.3 Gyx2 (B). Thereafter 1.6 Gyx2 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which 30 Gy was administered preoperatively in the first two protocols (A and B), while the whole dose was given preoperatively in the third protocol (C). The therapy was otherwise identical. Twenty mg doxorubicin was administered intravenously weekly. Surgery was possible in 40 patients. No patient failed to complete the protocol due to toxicity. In only 13 cases (24%) was death attributed to local failure. Five patients (9%) 'had a survival' exceeding 2 years. No signs of local recurrence were seen in 33 patients (60%); 5 out of 16 patients in Protocol A, 11 out of 17 patients in Protocol B, 17 out of 22 patients in Protocol C (P=0.017). In the 40 patients undergoing additional surgery, no signs of local recurrence were seen in 5 out of 9 patients, 11 out of 14 patients and 17 out of 17 patients, respectively (P=0.005).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Neoplasm Recurrence
653 a Middle Age
653 a Male
653 a Lung Neoplasms : secondary
653 a Human
653 a Female
653 a Feasibility Studies
653 a Doxorubicin : therapeutic use
653 a Dose Fractionation
653 a Combined Modality Therapy
653 a Clinical Protocols
653 a Carcinoma : therapy
653 a Carcinoma : pathology
653 a Carcinoma : mortality
653 a Anthracycline : therapeutic use
653 a Antibiotics
653 a 80 and over
653 a Aged
653 a Local
653 a Postoperative Care
653 a Prospective Studies
653 a Quality of Life
653 a Survival Rate
653 a Thyroid Neoplasms : mortality
653 a Thyroid Neoplasms : pathology
653 a Thyroid Neoplasms : therapy
7001 a Lundell, Gu Karolinska Institutet4 aut
7001 a Wahlberg, Peteru Lund University,Lunds universitet,Öron-, näs- och halssjukdomar, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Otorhinolaryngology (Lund),Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onh-pwa
7001 a Bergenfelz, Andersu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-abe
7001 a Grimelius, L4 aut
7001 a Åkerman, Månsu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-mak
7001 a Hjelm Skog, A-L4 aut
7001 a Wallin, Gu Karolinska Institutet4 aut
7102 a Bröstcancer-genetikb Sektion I4 org
7730 t British Journal of Cancerd : Springer Science and Business Media LLCg 86:12, s. 1848-1853q 86:12<1848-1853x 1532-1827x 0007-0920
8564 u http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12085174&dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1038/sj.bjc.6600361y FULLTEXT
8564 u https://doi.org/10.1038/sj.bjc.6600361
8564 8u https://lup.lub.lu.se/record/109024
8564 8u https://doi.org/10.1038/sj.bjc.6600361
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1951485

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy